Compare BIIB & UMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIIB | UMC |
|---|---|---|
| Founded | 1978 | 1980 |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2B | 20.4B |
| IPO Year | 1991 | 2000 |
| Metric | BIIB | UMC |
|---|---|---|
| Price | $173.85 | $7.86 |
| Analyst Decision | Buy | Strong Sell |
| Analyst Count | 22 | 1 |
| Target Price | ★ $177.40 | N/A |
| AVG Volume (30 Days) | 2.0M | ★ 8.8M |
| Earning Date | 10-30-2025 | 01-20-2026 |
| Dividend Yield | N/A | ★ 4.72% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 10.97 | 0.10 |
| Revenue | ★ $10,065,900,000.00 | $7,746,022,974.00 |
| Revenue This Year | $3.61 | $3.20 |
| Revenue Next Year | N/A | $6.45 |
| P/E Ratio | $15.86 | ★ $14.86 |
| Revenue Growth | ★ 4.77 | 4.08 |
| 52 Week Low | $110.04 | $5.61 |
| 52 Week High | $185.17 | $8.33 |
| Indicator | BIIB | UMC |
|---|---|---|
| Relative Strength Index (RSI) | 55.20 | 58.81 |
| Support Level | $169.24 | $7.78 |
| Resistance Level | $180.79 | $8.10 |
| Average True Range (ATR) | 4.98 | 0.14 |
| MACD | -1.64 | 0.03 |
| Stochastic Oscillator | 35.73 | 76.32 |
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 5% market share in 2024 after TSMC and SMIC. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the US, and South Korea. UMC features a diverse customer base that includes Texas Instruments, MediaTek, Intel, Broadcom, Novatek, and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 19,000 people as of February 2025.